|Nimodipine (Code C692)|
|Terms & Properties|
Preferred Name: Nimodipine
Definition: A dihydropyridine derivative and an analogue of the calcium channel blocker nifedipine, with antihypertensive activity. Nimodipine inhibits the transmembrane influx of calcium ions in response to depolarization in smooth muscle cells, thereby inhibiting vascular smooth muscle contraction and inducing vasodilatation. Nimodipine has a greater effect on cerebral arteries than on peripheral smooth muscle cells and myocardial cells, probably because this agent can cross the blood brain barrier due to its lipophilic nature. Furthermore, this agent also inhibits the drug efflux pump P-glycoprotein, which is overexpressed in some multi-drug resistant tumors, and may improve the efficacy of some antineoplastic agents.
NCI-GLOSS Definition: Belongs to a family of drugs called calcium channel blockers. It is being investigated for use with anticancer drugs to prevent or overcome drug resistance and improve response to chemotherapy.
NCI Metathesaurus Link: C0678207 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|CAS Registry Number||66085-59-4 (see NLM ChemIDplus info)|
|FDA UNII Code||57WA9QZ5WH|
|ChEBI ID||CHEBI:7575 (see ChEBI info)|
|PDQ Closed Trial Search ID||41210|
|PDQ Open Trial Search ID||41210 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|